Promising ternary dry powder inhaler formulations of cromolyn sodium: Formulation and in vitro-in vivo evaluation

Archives of Pharmacal Research

Volumn 30, Issue 6, 2007, Pages 785-792

  Elbary, Ahmed Abd ^a   El laithy, Hanan M ^a   Tadros, Mina I ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Aerosil 200; Alternative carriers; Dry powder inhaler; Glucose monohydrate; Sorbitol

Indexed keywords

EID: 34347404313     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02977643     Document Type: Article

References (30)

1. Aswania, O. A. and Chrystyn, H., Relative lung bioavailability of generic sodium cromoglycate inhalers used with and without a spacer device. Pulmon. Pharmaco. Ther., 14, 129-133 (2001).
2. Bode, R., Ferch, H., and Fratzscher, H., Technical Bulletin Aerosil, No. 4. Nippon Aerosil, p. 4 (1967).
3. British Pharmacopoeia, Aerodynamic assessment of fine particles, British Pharmacopoeia Commission, HMSO, London, Appendix XII F, A194- A200 (2000).
4. Byron, P. R., Drug delivery devices: issues in drug development. The Proceedings of the American Thoracic Society, 1, 321-328 (2004).
5. Chen, L. R., Young, V. G., Ballesteros, D. L., and Grant, D. J. W., Solid state behavior of cromolyn sodium hydrates. J. Pharm. Sci., 88, 1191-1200 (1999).
6. Chew, N. Y. K. and Chan, H. K., In vitro aerosol performance and dose uniformity between the Foradil® Aerolizer® and the Oxis® Turbuhaler®. J. Aerosol. Med. Winter, 14, 495-501 (2001).
7. Chew, N. Y. K., Bagster, D. A., and Chan, H. K., Effect of particle size, air flow and inhaler device on the aerosolization of disodium cromoglycate powders. Int. J. Pharm., 206, 75-83 (2000).
8. nd edition, C338-C342. New York: Churchill Livingstone (1999).
9. Gardner, J.J., Determination of sodium cromoglycate in human urine by high performance liquid chromatography on an anion exchange column. J. Chromatogr., 305, 228-232 (1984).
10. Glasnapp, A., Alternatives for the lactose-intolerant patient. Int. J. Pharm. Compound, 2, 412-413 (1998).
11. Hinrichs, W. L. J., Prinsen. M. G., and Frijlink H. W., Inulin glasses for the stabilization of therapeutic proteins. Int. J. Pharm., 215, 163-174 (2001).
12. Kawashima, Y., Serigano, T., Hino, T., Yamamoto, H., and Takeuch,i H., Effect of surface morphology of carrier lactose on dry powder inhalation property of pranlukast hydrate. Int. J. Pharm., 172, 179-188 (1998).
13. Kawashima, Y., Serigano T., Hino T., Yamamoto H., and Takeuchi, H., Design of inhalation dry powder of pranlukast hydrate to improve dispersibility by surface modification with light anhydrous silicic acid (Aerosil® 200). Ibid., 173, 243-251 (1998).
14. Keller, M. and Muller, R., Dry powder for inhalation, Inter. Patent WO, 00/28979 (2000).
15. rd Edn., New York: American Pharmaceutical Association and Pharmaceutical Press (2000).
16. Larhrib, H., Zeng, X. M., Martin, G. P., Marriott, C., and Pritchard, J., The use of different grades of lactose as a carrier for aerosolized salbutamol sulfate. Int. J. Pharm., 191, 1-14 (1999).
17. Lehto, V. P. and Lankinen, T., Moisture transfer into medicament chambers equipped with a double barrier desiccant system. Int. J. Pharm., 275, 155-164 (2004).
18. nd edition. 970-971. London: The Pharmaceutical Press, (1986).
19. Nowak-Wegrzyn, A., Shapiro, G. G., Beyer, K., Bardina, L., and Sampson, H. A., Contamination of dry powder inhalers for asthma with milk proteins containing lactose. J. Allergy and Clinical Immunology, 113, 558-60 (2004).
20. Patton, J. S. and Platz, R. M., Pulmonary delivery of peptides and proteins for systemic action. Adv. Drug Deliv. Rev., 8, 179-228 (1992).
21. Sethuraman, V. V. and Hickey, A. J., Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug. AAPS Pharm. Sci.Tech., 3, 1-10 (2002).
22. Srichana, T., Martin, G. P., and Mariott, C., Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro, Eur. J. Pharm. Sci., 7, 73-80 (1998).
23. Staniforth, J.N., Preformulation aspects of dry powder aerosols. Drug Deliv., 5, 65-73 (1996).
24. Steckel, H. and Bolzen, N., Alternative sugars as potential carriers for dry powder inhalations. Int. J. Pharm., 270, 297-306 (2004).
25. Tee, S. K., Marriott, C., Zeng, X. M., and Martin, G. P., The use of different sugars as fine and coarse carriers for aerosolized salbutamol sulfate. Ibid., 208, 111-123 (2000).
26. Thompson, D. C., Pharmacology of therapeutic aerosols, In Pharmaceutical inhalation aerosol technology, ed. A. J. Hickey, 155-185. New York: Marcel Dekker (1992).
27. Timsina, M. P., Martin G. P., Marriott C., Ganderton D., and Yianneskis, M., Drug delivery to the respiratory tract using dry powder inhalers. Int. J. Pharm., 101, 1-13 (1994).
28. Vidgren, M., Karkkainen, A., Karjalainen, P., Paronen, T. P., and Nuutinen, J., Effect of powder inhaler design on drug deposition in the respiratory tract. Ibid., 42, 211-216 (1988).
29. Yu, L., Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv. Drug Deliv. Rev., 48, 27-42 (2001).
30. Zeng, X. M., Martin, G. P., Marriott, C., and Pritchard, J., The influence of carrier morphology on drug delivery by dry powder inhalers. Int. J. Pharm., 200, 93-106 (2000).